Assay.Works is a provider for research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work. They specialize in assay development and optimization (with both customer-provided and de-novo designed assay formats), quantitative biology, high-throughput screening, and in vitro biactivity assessment.
We partner with assay works for joint biochemical/biophysical high-throughput screening campaings, lab-automation, and (tool)compound libraries.
By bringing together modern label-free technology, application development know-how and sophisticated software, Creoptix offers a unique optical biosensor tool for binding kinetics. Engineered around our proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment.
2bind is Creoptix’ technology and service partner. We work together in testing novel developments, setting up assay formats and furthering the GCI technology.
Oncodesign is a biopharmaceutical company that fills in the innovation gaps in the healthcare industry, based on its unique precision medicine platform. Oncodesign’s goal is to discover new innovative therapies effective against cancers and serious illnesses without known treatment.
2bind is Oncodesign’s exclusive partner for MST and nanoDSF hit identification, validation, and characterization in the intregrated drug discovery platorm DRIVE™. This platform offers a complete drug discovery and development solution through the whole value chain from hit finding to IND filing, aiming to accelerate the entry of the client new chemical entities into clinic within a 3 to 4 years timeframe to deliver an IND.
PharmAI is a Bio-IT provider for innovative Focused Library Services, which allow for a reduction of high-throughput-screening complexitiy by reducing the initial size of the screening compound or fragment library by computational methods. Up to millions of virtual (but physically available) compounds can be screened to generate a diversified and focused chemical screening space.
2bind is PharmAI’s exclusive in-vitro validation partner. Benefit from the power of combined ultra-high-throughput in silico screening by PharmAI and high-throughput biophysical validation of predicted hits by 2bind.
NanoTemper Technologies is a device manufacturer that specializes in developing and producing cutting-edge biophysical instruments for the characterization of biomolecules and molecular interactions. NanoTemper’s key technologies are MST (MicroScale Thermophoresis) and nanoDSF (nano-scale Differential Scanning Fluorimetry). 2bind’s biophysical drug discovery, interaction analysis, and screening services often use NanoTemper technologies.
We partner with NanoTemper Technologies for beta-testing of novel technologies and instruments, optimization and use-testing of existing technologies, and production of application and information materials. 2bind is certified for the MST and nanoDSF technologies by NanoTemper.
Dynamic Biosensors is a device manufacturer that specializes in development and production of analytical systems for the characterization of biomolecules and molecular interactions. Their key technology is swithSENSE, a novel approach for measuring almost all parameters of molecular interactions, including affinities and kinetics.
2bind partners with Dynamic Biosensors for testing of novel technologies and instrument formats as well as assay and method development.
Inoviem Scientific is a provider for developing and applying technologies that help improving drug discovery lead compound selection and reduce hit attritions rates during drug development. Additional service areas are mass spectrometry-based on- and off-target analysis and target deconvolution.
We partner with Inoviem Scientific to give our clients and customers access to their services during drug discovery or development programs. For example, 2bind customers can choose to combine off-target analysis to a known ligand and target with in vitro validation of these predictions.
trenzyme is an ISO 9001 certified research service provider offering a wide range of highly customized services in recombinant protein production and cell line development.
Since 2000, trenzyme’s highly skilled scientific experts provide a one-stop-shop from expression construct design and cloning to recombinant target expression in different host systems like E.coli, Yeast, insect and mammalian cells. The portfolio is enriched by development of stable assay cell lines based on the proprietary ExoIN technology and GMP-compliant production cell line development based on the proven CHOvolutionTM platform.
We partner with trenzyme for providing our screening campaigns with high quality recombinant target proteins tailored to the needs of the client and the project.
CrystalsFirst’s technology is disrupting the access to structural data for exploration of the vast chemical space. CrystalsFirst‘s proprietary platform has a track record of successes in hit identification with hard-to-hit targets, esp. for oncology targets or E3 ligases, and reliable access to bio-structural data on scale, e.g. hit-to-lead. The combination with large-scale chemoinformatics enables a rapid exploration of the chemical space to secure the IP and increase the return on R&D investments.
We partner with CrystalsFirst for providing our clients rapid access to their proprietary crystallization platform, high-performance soaking systems as well as structure-guided support for compound- and fragment-based screening.
Since June 2014, Ralf is chairing the Lophius supervisory board to coordinate strategic activities and support the companies further development.
Prior to that, he served almost 13 years as CEO of GENEART AG, a German biotech company, which he founded in 1999 as spin-off of his research group at the University of Regensburg. Under his leadership, GENEART went public in 2006 at the Frankfurt stock exchange and was acquired by Life Technologies in 2010. As CEO and VP Synthetic Biology, he also coordinated the integration activities of the Regensburg based GENEART into the US Company.
Ralf is also Professor for Medical Microbiology and Gene Therapy and member of the Medical Faculty of the University of Regensburg. Beside his management and scientific skills, he brings an excellent professional network of partners in academic research, pharma and biotech industry as well as financing.